Triptorelin
D-Trp6-LHRH, triptorelin acetate, triptorelin pamoate, triptorelin embonate, GnRH agonist
Triptorelin is a long-acting synthetic analogue of gonadotrophin-releasing hormone. Given continuously it shuts the reproductive axis down rather than stimulating it, which is the basis of its approved uses in advanced prostate cancer, central precocious puberty, endometriosis and fibroids. It is a real licensed medicine with decades of controlled data behind it - and it is being sold online for a purpose (restarting a suppressed axis) that runs directly against its designed pharmacology.
Mechanism
Triptorelin is native GnRH with a single substitution - D-tryptophan replacing glycine at position 6 - which resists enzymatic degradation and increases receptor affinity roughly a hundredfold. Its therapeutic effect turns on a paradox in GnRH receptor biology. The pituitary gonadotroph responds to GnRH only when it arrives in pulses, roughly every 60 to 90 minutes. Continuous occupancy of the receptor causes downregulation and uncoupling within one to two weeks, shutting off LH and FSH secretion and therefore gonadal steroid production. A sustained-release triptorelin depot provides exactly that continuous exposure.
The immediate consequence is the opposite of the eventual one. For the first 7 to 14 days there is a 'flare' - a surge of LH, FSH and testosterone or oestradiol - before suppression sets in. In advanced prostate cancer this flare can transiently worsen bone pain, spinal cord compression or urinary obstruction, which is why an antiandrogen is commonly given alongside during the first weeks. After downregulation, testosterone falls to castrate levels and stays there for the duration of the depot; in a pooled analysis of 920 patients across nine studies, 79%, 92%, 93%, 90% and 91% were below 20 ng/dL at 1, 3, 6, 9 and 12 months respectively. Recovery of the axis after discontinuation takes months.
A note on taxonomy: triptorelin is grouped here with the melanocortin, reproductive and pituitary peptides for navigational convenience. It is a GnRH analogue and has no melanocortin receptor activity.
What the research shows
Triptorelin has three well-evidenced clinical settings. In advanced prostate cancer, a randomised comparison against leuprolide in 284 men (140 triptorelin, 144 leuprolide) over nine monthly injections found that triptorelin lowered testosterone slightly more slowly at day 29 (91.2% versus 99.3% at castrate levels) but was equivalent from day 57 onwards and maintained castration equally well through day 253. Nine-month survival was 97.0% with triptorelin versus 90.5% with leuprolide (p=0.033), though survival was not the trial's powered endpoint and that difference should not be over-read. A subsequent pooled retrospective analysis of 920 patients across nine studies confirmed that the 1-, 3- and 6-month depots achieve and maintain testosterone below 20 ng/dL in 80-97% of patients across the dosing interval. In central precocious puberty, a 48-week international trial of the 22.5 mg six-month formulation in 44 treatment-naive children (39 girls, 5 boys) across 18 centres found 41 of 44 (93.2%) had prepubertal stimulated LH at month 6, sustained to month 12. That trial was single-arm and small - characteristic of paediatric endocrinology, where the disease is uncommon and a placebo arm is hard to justify - but the biochemical endpoint is unambiguous and the class effect has been established for decades. Triptorelin is also used in endometriosis, uterine fibroids and IVF protocols, and, more contentiously and on a considerably weaker evidence base, as a puberty-suppressing agent in gender-dysphoric young people.
The area where triptorelin is genuinely unevidenced is precisely where the online peptide market has placed it: as an intermittent low-dose agent to restart the hypothalamic-pituitary-gonadal axis after anabolic steroid use or after suppression. That use exploits the acute stimulatory flare phase of a GnRH agonist rather than its designed suppressive phase, and there are no controlled trials supporting it. Given that the drug's entire mechanism is receptor downregulation under sustained exposure, repeated dosing risks producing the suppression it is being taken to reverse. This is not a subtle point - it is the drug working exactly as designed, in a direction opposite to the user's intent.
Evidence assessment
High-quality evidence
Multiple regulator-approved indications supported by a randomised active-comparator trial in prostate cancer, a pooled analysis of 920 patients showing sustained castration, and a prospective phase 3 trial with unambiguous biochemical endpoints in central precocious puberty, backed by decades of post-marketing use.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer High-quality evidence
Castrate testosterone was reached slightly less rapidly with triptorelin at day 29 (91.2% vs 99.3%) but was equivalent from day 57 and maintained equally through day 253; nine-month survival was 97.0% vs 90.5% (p=0.033), an unpowered secondary observation.
Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty Mixed evidence
41 of 44 children (93.2%) had prepubertal stimulated LH (≤5 IU/L) at month 6, maintained through month 12, with no unexpected drug-related adverse events.
Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer Mixed evidence
79%, 92%, 93%, 90% and 91% of patients reached testosterone below 20 ng/dL at 1, 3, 6, 9 and 12 months; individual formulations achieved 80-97%, with median end-of-study testosterone of 2.9-14.1 ng/dL.
Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency Mixed evidence
Peak concentrations were similar across all four groups, but clearance fell with renal dysfunction and was lowest in hepatic impairment; elimination half-life was about 2.8 hours in healthy volunteers versus about 7.6 hours in impaired subjects. The authors concluded the liver plays the predominant role in triptorelin clearance.
Safety
The predictable consequences of induced hypogonadism dominate the adverse-effect profile: hot flushes, loss of libido, erectile dysfunction, fatigue, mood disturbance, and with prolonged use loss of bone mineral density, loss of lean mass, insulin resistance and adverse lipid changes. Androgen deprivation in prostate cancer is associated with increased cardiovascular risk in observational data. Tumour flare in the first two weeks can precipitate spinal cord compression or ureteric obstruction in men with extensive metastatic disease, which is why antiandrogen cover is standard. Injection-site reactions are common. In children treated for precocious puberty, headache, hot flushes and injection-site pain are frequent, and there are post-marketing reports of pseudotumour cerebri and of seizures. Rare cases of pituitary apoplexy have been reported after a first dose, almost always in the presence of an undiagnosed pituitary adenoma. Bone density loss is the principal reason for limiting treatment duration in benign gynaecological indications, and add-back hormone therapy is often used. Triptorelin is contraindicated in pregnancy. Clearance is reduced in hepatic and renal impairment, with the liver playing the predominant role in elimination. Unsupervised use carries all these risks with none of the monitoring - bone densitometry, testosterone measurement, specialist oversight - that the licensed indications are built around.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Licensed by the MHRA in sustained-release formulations for advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and as part of controlled ovarian stimulation protocols in assisted reproduction. Prescription-only medicine, generally initiated by a specialist. |
| United States | FDA-approved in depot formulations (3.75 mg monthly, 11.25 mg three-monthly, 22.5 mg six-monthly) for palliative treatment of advanced prostate cancer, and as a 22.5 mg six-monthly formulation for central precocious puberty in children aged 2 years and older. Prescription-only. |
| WADA (sport) | Prohibited in males at all times. WADA's Prohibited List section S2.2.1 covers luteinising hormone and chorionic gonadotrophin and their releasing factors in males, and triptorelin is among the GnRH agonist analogues named as examples, prohibited both in and out of competition. |
Questions
Both, in sequence, and this trips people up constantly. For the first one to two weeks it causes a surge - the flare - because it is a GnRH receptor agonist. Then the receptor downregulates under continuous stimulation, and testosterone falls to castrate levels and stays there. The suppressive phase is the therapeutic one; the flare is a managed side effect, not the intended action.
There are no controlled trials supporting this, and the pharmacology argues against it. That use relies on the brief stimulatory flare, but the drug is specifically designed to produce sustained receptor occupancy, which downregulates the pituitary. Repeated dosing risks reproducing exactly the suppression the person is trying to escape. This is a case where the marketing has attached itself to a real drug for a use the drug was engineered to do the opposite of.
Because in males, the acute effect of a GnRH agonist is to raise LH and therefore endogenous testosterone, which is performance-relevant. WADA lists it under the LH and chorionic gonadotrophin releasing-factor category, prohibited in males at all times. In females the equivalent stimulation does not produce a comparable androgenic advantage, so the prohibition is sex-specific.
They follow from sustained hypogonadism: loss of bone mineral density, loss of lean mass, insulin resistance, adverse lipid changes, hot flushes, fatigue and mood disturbance, and in prostate cancer an association with increased cardiovascular risk in observational data. These are why licensed use involves bone density monitoring, defined treatment durations for benign conditions, and often hormonal add-back therapy - none of which accompanies unsupervised use.